Which has stronger earnings and valuation, MXCT or VRCI?

Verici Dx has lower revenue, but higher earnings than MaxCyte. Verici Dx is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MaxCyte £32.29M 0.04 -£45.08M -£40.00 N/A Verici Dx £3.66M 1.25 -£6.56M -£0.90 N/A

Is MXCT or VRCI more profitable?

MaxCyte has a net margin of -119.69% compared to Verici Dx's net margin of -193.05%. MaxCyte's return on equity of -11.59% beat Verici Dx's return on equity. Company Net Margins Return on Equity Return on Assets MaxCyte -119.69% -11.59% -11.07% Verici Dx -193.05% -138.93% -26.14%

Does the media prefer MXCT or VRCI?

In the previous week, MaxCyte and MaxCyte both had 1 articles in the media. MaxCyte's average media sentiment score of 0.00 beat Verici Dx's score of -1.31 indicating that MaxCyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verici Dx 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media prefer MXCT or IDHC?

In the previous week, MaxCyte and MaxCyte both had 1 articles in the media. MaxCyte's average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Integrated Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, LLAI or MXCT?

LungLife AI has higher earnings, but lower revenue than MaxCyte. LungLife AI is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LungLife AI £33.87K 34.24 -£5.22M -£12.58 N/A MaxCyte £32.29M 0.04 -£45.08M -£40.00 N/A

Is LLAI or MXCT more profitable?

MaxCyte has a net margin of -119.69% compared to LungLife AI's net margin of -11,767.39%. MaxCyte's return on equity of -11.59% beat LungLife AI's return on equity. Company Net Margins Return on Equity Return on Assets LungLife AI -11,767.39% -51.42% -27.28% MaxCyte -119.69% -11.59% -11.07%

MaxCyte (MXCT) Competitors

GBX 1.19 -0.03 (-2.46%)

As of 09/10/2026

Compare

MXCT vs. VRCI, IDHC, DMTR, LLAI, and LLA

Should you buy MaxCyte stock or one of its competitors? MaxCyte's main competitors and comparable companies include Verici Dx (VRCI), Integrated Diagnostics (IDHC), Deepmatter Group (DMTR), LungLife AI (LLAI), and LLA.L,0P0001T9GN,0 (LLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does MaxCyte compare to Verici Dx?

MaxCyte (LON:MXCT) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

In the previous week, MaxCyte and MaxCyte both had 1 articles in the media. MaxCyte's average media sentiment score of 0.00 beat Verici Dx's score of -1.31 indicating that MaxCyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verici Dx	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

MaxCyte has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Verici Dx has a beta of 1.222, indicating that its stock price is 22% more volatile than the broader market.

MaxCyte has a net margin of -119.69% compared to Verici Dx's net margin of -193.05%. MaxCyte's return on equity of -11.59% beat Verici Dx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-119.69%	-11.59%	-11.07%
Verici Dx	-193.05%	-138.93%	-26.14%

Verici Dx has lower revenue, but higher earnings than MaxCyte. Verici Dx is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	£32.29M	0.04	-£45.08M	-£40.00	N/A
Verici Dx	£3.66M	1.25	-£6.56M	-£0.90	N/A

24.0% of MaxCyte shares are owned by institutional investors. Comparatively, 15.9% of Verici Dx shares are owned by institutional investors. 1.9% of MaxCyte shares are owned by insiders. Comparatively, 1.2% of Verici Dx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

MaxCyte beats Verici Dx on 8 of the 12 factors compared between the two stocks.

How does MaxCyte compare to Integrated Diagnostics?

MaxCyte (LON:MXCT) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

MaxCyte has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.432, suggesting that its share price is 57% less volatile than the broader market.

Integrated Diagnostics has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	£32.29M	0.04	-£45.08M	-£40.00	N/A
Integrated Diagnostics	£8.35B	0.00	£4.01T	£250.03	0.00

Integrated Diagnostics has a net margin of 16.49% compared to MaxCyte's net margin of -119.69%. Integrated Diagnostics' return on equity of 39.61% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-119.69%	-11.59%	-11.07%
Integrated Diagnostics	16.49%	39.61%	9.69%

24.0% of MaxCyte shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 1.9% of MaxCyte shares are held by company insiders. Comparatively, 78.4% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, MaxCyte and MaxCyte both had 1 articles in the media. MaxCyte's average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integrated Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Integrated Diagnostics beats MaxCyte on 8 of the 11 factors compared between the two stocks.

How does MaxCyte compare to Deepmatter Group?

Deepmatter Group (LON:DMTR) and MaxCyte (LON:MXCT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

24.0% of MaxCyte shares are held by institutional investors. 1.9% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Deepmatter Group has higher earnings, but lower revenue than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Deepmatter Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Deepmatter Group	£1.04M	0.00	N/A	-£0.30	N/A
MaxCyte	£32.29M	0.04	-£45.08M	-£40.00	N/A

Deepmatter Group has a net margin of 0.00% compared to MaxCyte's net margin of -119.69%. Deepmatter Group's return on equity of 0.00% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Deepmatter Group	N/A	N/A	N/A
MaxCyte	-119.69%	-11.59%	-11.07%

In the previous week, MaxCyte had 1 more articles in the media than Deepmatter Group. MarketBeat recorded 1 mentions for MaxCyte and 0 mentions for Deepmatter Group. Deepmatter Group's average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company	Overall Sentiment
Deepmatter Group	Neutral
MaxCyte	Neutral

Summary

MaxCyte beats Deepmatter Group on 5 of the 9 factors compared between the two stocks.

How does MaxCyte compare to LungLife AI?

LungLife AI (LON:LLAI) and MaxCyte (LON:MXCT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

42.5% of LungLife AI shares are held by institutional investors. Comparatively, 24.0% of MaxCyte shares are held by institutional investors. 48.4% of LungLife AI shares are held by company insiders. Comparatively, 1.9% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, MaxCyte had 1 more articles in the media than LungLife AI. MarketBeat recorded 1 mentions for MaxCyte and 0 mentions for LungLife AI. LungLife AI's average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company	Overall Sentiment
LungLife AI	Neutral
MaxCyte	Neutral

LungLife AI has higher earnings, but lower revenue than MaxCyte. LungLife AI is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LungLife AI	£33.87K	34.24	-£5.22M	-£12.58	N/A
MaxCyte	£32.29M	0.04	-£45.08M	-£40.00	N/A

LungLife AI has a beta of -0.3, meaning that its stock price is 130% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

MaxCyte has a net margin of -119.69% compared to LungLife AI's net margin of -11,767.39%. MaxCyte's return on equity of -11.59% beat LungLife AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LungLife AI	-11,767.39%	-51.42%	-27.28%
MaxCyte	-119.69%	-11.59%	-11.07%

Summary

MaxCyte beats LungLife AI on 7 of the 12 factors compared between the two stocks.

How does MaxCyte compare to LLA.L,0P0001T9GN,0?

LLA.L,0P0001T9GN,0 (LON:LLA) and MaxCyte (LON:MXCT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

LLA.L,0P0001T9GN,0 has a net margin of 0.00% compared to MaxCyte's net margin of -119.69%. MaxCyte's return on equity of -11.59% beat LLA.L,0P0001T9GN,0's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LLA.L,0P0001T9GN,0	N/A	-48.59%	-27.28%
MaxCyte	-119.69%	-11.59%	-11.07%

In the previous week, MaxCyte had 1 more articles in the media than LLA.L,0P0001T9GN,0. MarketBeat recorded 1 mentions for MaxCyte and 0 mentions for LLA.L,0P0001T9GN,0. LLA.L,0P0001T9GN,0's average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company	Overall Sentiment
LLA.L,0P0001T9GN,0	Neutral
MaxCyte	Neutral

LLA.L,0P0001T9GN,0 has higher earnings, but lower revenue than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than LLA.L,0P0001T9GN,0, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LLA.L,0P0001T9GN,0	N/A	N/A	-£4.47M	-£0.12	N/A
MaxCyte	£32.29M	0.04	-£45.08M	-£40.00	N/A

5.4% of LLA.L,0P0001T9GN,0 shares are held by institutional investors. Comparatively, 24.0% of MaxCyte shares are held by institutional investors. 1.9% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

LLA.L,0P0001T9GN,0 has a beta of -0.3, indicating that its share price is 130% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Summary

MaxCyte beats LLA.L,0P0001T9GN,0 on 8 of the 11 factors compared between the two stocks.

Get MaxCyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MXCT vs. The Competition

Export

Metric	MaxCyte	Life Sciences Tools & Services Industry	Healthcare Sector	LON Exchange
Market Cap	£1.27M	£9.74B	£7.16B	£2.51B
Dividend Yield	N/A	1.47%	2.57%	6.24%
P/E Ratio	-0.03	66.42	274.94	366.83
Price / Sales	0.04	108.69	685.45	89,753.13
Price / Cash	1.97	26.35	76.65	27.89
Price / Book	0.01	5.28	10.33	6.33
Net Income	-£45.08M	£56.67B	£3.50B	£5.89B
7 Day Performance	-5.56%	-2.15%	-3.32%	-0.69%
1 Month Performance	-4.03%	-1.93%	-0.53%	0.00%
1 Year Performance	-19.59%	25.04%	23.51%	19.96%

MaxCyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MXCT MaxCyte	N/A	GBX 1.19 -2.5%	N/A	-16.2%	£1.27M	£32.29M	N/A	80	News Coverage High Trading Volume
VRCI Verici Dx	N/A	GBX 0.21 -7.6%	N/A	-60.0%	£4.76M	£3.66M	N/A	19	Gap Down
IDHC Integrated Diagnostics	N/A	GBX 0.53 -3.6%	N/A	-4.6%	£3.08M	£8.35B	0.00	6,692	News Coverage Gap Down
DMTR Deepmatter Group	N/A	N/A	N/A	N/A	£1.33M	£1.04M	N/A	N/A	Gap Down
LLAI LungLife AI	N/A	GBX 3.50 -17.6%	N/A	+0.0%	£1.16M	£33.87K	N/A	15	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:MXCT) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MaxCyte (MXCT) Competitors

MXCT vs. VRCI, IDHC, DMTR, LLAI, and LLA

How does MaxCyte compare to Verici Dx?

Summary

How does MaxCyte compare to Integrated Diagnostics?

Summary

How does MaxCyte compare to Deepmatter Group?

Summary

How does MaxCyte compare to LungLife AI?

Summary

How does MaxCyte compare to LLA.L,0P0001T9GN,0?

Summary

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MaxCyte (MXCT) Competitors

MXCT vs. VRCI, IDHC, DMTR, LLAI, and LLA

How does MaxCyte compare to Verici Dx?

Does the media prefer MXCT or VRCI?

Which has more risk and volatility, MXCT or VRCI?

Is MXCT or VRCI more profitable?

Which has stronger earnings and valuation, MXCT or VRCI?

Do institutionals and insiders have more ownership in MXCT or VRCI?

Summary

How does MaxCyte compare to Integrated Diagnostics?

Which has more risk & volatility, MXCT or IDHC?

Which has better earnings and valuation, MXCT or IDHC?

Is MXCT or IDHC more profitable?

Do insiders and institutionals hold more shares of MXCT or IDHC?

Does the media prefer MXCT or IDHC?

Summary

How does MaxCyte compare to Deepmatter Group?

Do insiders and institutionals believe in DMTR or MXCT?

Which has preferable earnings and valuation, DMTR or MXCT?

Is DMTR or MXCT more profitable?

Does the media favor DMTR or MXCT?

Summary

How does MaxCyte compare to LungLife AI?

Do institutionals and insiders have more ownership in LLAI or MXCT?

Does the media prefer LLAI or MXCT?

Which has better valuation and earnings, LLAI or MXCT?

Which has more volatility & risk, LLAI or MXCT?

Is LLAI or MXCT more profitable?

Summary

How does MaxCyte compare to LLA.L,0P0001T9GN,0?

Is LLA or MXCT more profitable?

Does the media prefer LLA or MXCT?

Which has better valuation & earnings, LLA or MXCT?

Do institutionals and insiders hold more shares of LLA or MXCT?

Which has more risk & volatility, LLA or MXCT?

Summary

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools